Charles River Labs (CRL) PT Raised to $301 at Credit Suisse

February 17, 2021 4:13 PM EST
Get Alerts CRL Hot Sheet
Price: $306.40 +0.39%

Rating Summary:
    20 Buy, 6 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 14 | New: 42
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Credit Suisse analyst Erin Wilson Wright raised the price target on Charles River Labs (NYSE: CRL) to $301.00 (from $259.00) while maintaining a Neutral rating.

The analyst comments "CRL’s 4Q EPS ($2.39) handily exceeded our $2.04 on stronger revenues and profitability. Below the line factors also added $0.15. It unveiled encouraging ‘21 EPS guidance of $9.00-$9.25 (vs. cons. $8.89), reflecting org. revenue growth of +9%-11% (encompassing our est. +10.5%), contributions from its Citoxlab and HemaCare acquisitions (+50-100 bps), and favorable FX (+200-250 bps), as well as continued operating margin improvement. Our TP moves to $301 (29.5x ‘22 EPS) from $259 on the notably higher view and greater conviction in its LT growth prospects with its acquisition of Cognate (details below). Risks: Demand shifts, biotech funding."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Credit Suisse, Definitive Agreement, Erin Wilson